GRAIL (GRAL) Stock Surges 22% Before Critical FDA Panel Meeting on Galleri Test

GRAIL (GRAL) stock soared 22% Monday ahead of the FDA advisory committee's Sept. 23 review of its Galleri multi-cancer early detection blood test.

The post GRAIL (GRAL) Stock Surges 22% Before Critical FDA Panel Meeting on Galleri Test appeared first on Blockonomi.